Edition:
United Kingdom

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

25.60USD
4:27pm BST
Change (% chg)

$-0.52 (-1.99%)
Prev Close
$26.12
Open
$25.54
Day's High
$25.67
Day's Low
$25.27
Volume
13,830
Avg. Vol
42,909
52-wk High
$38.85
52-wk Low
$22.65

Latest Key Developments (Source: Significant Developments)

Cellectis Operating Loss Widens To 21.7 Million US Dollars
Wednesday, 1 Aug 2018 

Aug 2 (Reuters) - CELLECTIS SA ::SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO.Q2 OPERATING LOSS $21.7 MLN VS $19.9 MLN YEAR AGO.Q2 NET LOSS $9.7 MLN VS $26.5 MLN YEAR AGO.END-H1 CASH POSITION OF $491 MLN EXPECTED TO FUND OPERATIONS UNTIL 2022.  Full Article

Calyxt Announces Upsizing And Pricing Of Follow-On Offering
Friday, 18 May 2018 

May 18 (Reuters) - Calyxt Inc ::CALYXT ANNOUNCES UPSIZING AND PRICING OF FOLLOW-ON OFFERING.CALYXT - PRICE OF FOLLOW-ON PUBLIC OFFERING OF 3.6 MILLION SHARES OF COMMON STOCK LAUNCHED MAY 15 HAS BEEN SET AT $15.00 PER SHARE.CALYXT INC - OFFERING WAS UPSIZED FROM 3.1 MILLION SHARES TO ACCOMMODATE CELLECTIS TO BUY 550,000 SHARES.  Full Article

Cellectis Qtrly Total Revenues And Other Income $8.1 Mln Vs $10.3 Mln
Monday, 7 May 2018 

May 7 (Reuters) - Cellectis SA ::CELLECTIS SA QTRLY TOTAL REVENUES AND OTHER INCOME $8.1 MILLION VERSUS $10.3 MILLION.CELLECTIS SA QTRLY LOSS PER SHARE $0.71.CELLECTIS SA QTRLY ADJUSTED LOSS PER SHARE $0.39.  Full Article

Cellectis Announces Pricing Of Follow On Offering
Thursday, 5 Apr 2018 

April 5 (Reuters) - Cellectis SA ::CELLECTIS ANNOUNCES PRICING OF FOLLOW-ON OFFERING.‍PRICE OF ITS OFFERING OF ADS LAUNCHED ON APRIL 3, 2018, HAS BEEN SET TODAY AT $31.00/ADS AND NUMBER OF OFFERED ADSS IS 5.6 MILLION.  Full Article

Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares
Tuesday, 3 Apr 2018 

April 4 (Reuters) - CELLECTIS SA ::ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS).EACH ADS REPRESENTS ONE ORDINARY SHARE OF CELLECTIS.TO GRANT UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 15 PCT OF AGGREGATE OFFERING SIZE.GOLDMAN SACHS, CITIGROUP AND BARCLAYS ARE ACTING AS BOOK-RUNNING MANAGERS.NOMURA IS LEAD MANAGER, OPPENHEIMER AND LADENBURG THALMANN ARE CO-MANAGERS.  Full Article

Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - CELLECTIS ::SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.STUDIES DEMONSTRATED SAFETY AND TOLERABILITY OF UCART19.STUDIES RESULTED IN 83-PCT COMPLETE REMISSION RATE ACROSS THE PATIENT POPULATION.IN 'CALM' TRIAL (UCART19 IN ADVANCED LYMPHOID MALIGNANCIES) FOR ADULTS, FIVE OUT OF SEVEN PATIENTS ACHIEVED MOLECULAR REMISSION AT DAY 28.'CALM' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED; CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.ONE PATIENT IN 'CALM' TRIAL DEVELOPED GRADE 4 CYTOKINE RELEASE SYNDROME AND NEUTROPENIC SEPSIS LEADING TO DEATH AT DAY 15.IN 'PALL' TRIAL (PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA) FOR CHILDREN, ALL FIVE PATIENTS ACHIEVED MOLECULAR REMISSION;.'PALL' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED.'PALL TRIAL': CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.  Full Article

Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer
Monday, 4 Dec 2017 

Dec 4 (Reuters) - CELLECTIS SA ::CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Cellectis says cash position at Sept. 30 of $304.1 million
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY: CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS AT SEPT 30 STOOD AT $304.1 MLN VS $271.2 MLN AT JUNE 30 .Q3 TOTAL REVENUES AND OTHER INCOME $7.3 MLN VS $12.6 MLN YEAR AGO.Q3 FINANCIAL LOSS $3.4 MLN VS LOSS OF $1.2 MLN YEAR AGO .Q3 NET LOSS ATTRIBUTABLE TO SHAREHOLDERS $26.2 MLN VS LOSS OF $14.1 MLN YEAR AGO.EXPECTS ITS CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATIONS INTO 2020.  Full Article

Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Cellectis SA :FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN.Says ‍working with investigators and clinical sites to obtain IRB'S approval on revised protocols and resume patient enrollment​.Cellectis SA says ‍agreed with FDA to decrease of cohort dose level to 6.25x10(4) UCART123 cells/ in Phase 1 UCART123 protocols​.  Full Article

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO